BioSpace News Archive

Boundless Bio, a clinical stage, next-generation precision oncology company developing innovative therapeutics directed against extrachromosomal DNA for patients with oncogene amplified cancers, announced the appointment of Jami Rubin as Chief Financial Officer.

INmune Bio, Inc. (NASDAQ: INMB) (the “Company”) today announced that it will host a conference call on Monday, August 7, 2023 at 4:30 PM Eastern Time to discuss results for its second quarter ended June 30, 2023 and to provide a corporate update.

Gain Therapeutics, Inc. today announced that members of management will participate in a fireside chat at the 2023 BTIG Virtual Biotechnology Conference on Tuesday, August 8 at 9:30 a.m. ET and host investor meetings.

Celcuity Inc. today announced that Brian Sullivan, Chairman, Chief Executive Officer, and Co-founder of Celcuity, will participate in one-on-one meetings at the BTIG Virtual Biotechnology Conference being held on August 7-8, 2023.

Cullinan Oncology, Inc. today announced its participation in the following upcoming investor conferences.

Reviva Pharmaceuticals Holdings, Inc. today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will be presenting at two upcoming investor conferences to be held in August 2023.

Inspire Medical Systems, Inc., a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, announced the addition of Charisse Y. Sparks, M.D., as Chief Medical Officer, effective July 27, 2023.

Alvotech announced the completion of a private placement, in an overseas directed offering directed solely into Iceland to professional clients or eligible counterparties, of subordinated convertible bonds denominated in Icelandic krona and US dollar for a par value of $100 million.

Invectys, Inc., a clinical-stage immuno-oncology company focused on developing novel therapies for advanced cancers, is pleased to announce the U.S. Food and Drug Administration has granted Fast Track designation to its revolutionary product, IVS-3001.

Positron Corporation is pleased to announce that in combination with its new Business Cooperative Partnership with Shenyang Intelligent Neuclear Medical Technology Co, a wholly owned subsidiary of Neusoft Medical Systems, Positron has agreed on terms to purchase the current inventory from the Company’s PET Joint Venture partner, Neusoft Positron Medical Systems.